Get the Stockscreener App
1.15
6.48%
0.07
After Hours:
1.10
-0.05
-4.35%
Pds Biotechnology Corporation stock is traded at $1.15, with a volume of 172.29K.
It is up +6.48% in the last 24 hours and down -16.06% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$1.08
Open:
$1.09
24h Volume:
172.29K
Relative Volume:
0.29
Market Cap:
$50.39M
Revenue:
-
Net Income/Loss:
$-40.56M
P/E Ratio:
-0.9829
EPS:
-1.17
Net Cash Flow:
$-35.28M
1W Performance:
+3.60%
1M Performance:
-16.06%
6M Performance:
-64.72%
1Y Performance:
-61.54%
1-Day Range:
$1.07
$1.16
1-Week Range:
$1.00
$1.16
52-Week Range:
$0.8505
$4.42
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Name
Pds Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.15 | 50.39M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corporation Stock (PDSB) Latest News
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting - The Manila Times
Raymond James Financial Inc. Takes Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Call Transcript - MSN
Pds Biotech Announces Pds01adc Clinical Data To Be Presented At The American Association For Cancer Research - MarketScreener
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 - The Globe and Mail
Blair William & Co. IL Purchases 35,757 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Virtu Financial LLC Takes $89,000 Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish - Asianet Newsable
HC Wainwright Has Lowered Expectations for PDS Biotechnology (NASDAQ:PDSB) Stock Price - Defense World
H.C. Wainwright cuts PDS Biotechnology stock target to $13 By Investing.com - Investing.com South Africa
H.C. Wainwright cuts PDS Biotechnology stock target to $13 - Investing.com India
PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
PDS Biotechnology Advances Cancer Immunotherapy Trials - TipRanks
Earnings call transcript: PDS Biotech Q4 2024 shows narrowed loss, stock rises By Investing.com - Investing.com South Africa
PDS Biotech commences phase 3 trial for HPV cancer therapy By Investing.com - Investing.com South Africa
PDS Biotech commences phase 3 trial for HPV cancer therapy - Investing.com
PDS Biotech Advances Cancer Immunotherapy with New Clinical Trial - TipRanks
Earnings call transcript: PDS Biotech Q4 2024 shows narrowed loss, stock rises - Investing.com
PDS Biotechnology Corp reports results for the quarter ended December 31Earnings Summary - TradingView
PDS BIOTECHNOLOGY Earnings Results: $PDSB Reports Quarterly Earnings - Nasdaq
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update - MarketScreener
A Look at PDS Biotechnology's Upcoming Earnings ReportPDS Biotechnology (NASDAQ:PDSB) - Benzinga
PDS Biotechnology Corp expected to post a loss of 28 cents a shareEarnings Preview - TradingView
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference - The Manila Times
PDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to Analysts - Insider Monkey
10 Penny Stocks With Huge Upside Potential According To Analysts - Insider Monkey
PDS Biotechnology (PDSB) Expected to Announce Quarterly Earnings on Wednesday - Defense World
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results - The Manila Times
PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright - Defense World
PDS Biotechnology at Life Sciences Virtual Investor Conference: Strategic Advances in Cancer Treatment - Investing.com Australia
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - Morningstar
PDS Biotech receives FDA clearance to start clinical study on new treatment for metastatic colorectal cancer - Marketscreener.com
PDS Biotechnology Receives FDA Clearance for Versamune MUC1 Trial in Colon Cancer - Marketscreener.com
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer - The Manila Times
PDS Biotech Leadership to Participate in March Conferences - The Manila Times
PDS Biotechnology commences trial for head and neck squamous cell carcinoma - Yahoo
H.C. Wainwright maintains $21 target on PDS Biotech stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains $21 target on PDS Biotech stock - Investing.com India
HC Wainwright Reiterates “Buy” Rating for PDS Biotechnology (NASDAQ:PDSB) - Defense World
Pds Biotechnology Corporation Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pds Biotechnology Corporation Stock (PDSB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Glover Stephen C. | Director |
Feb 28 '25 |
Buy |
1.66 |
15,061 |
25,001 |
78,851 |
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):